About Wyeth
Wyeth is one of the world's leading pharmaceutical and healthcare products companies. We are research-driven, with a major focus on developing innovative new medicines that really make a difference to people's lives and address significant areas of unmet medical need.
Wyeth has an immensely strong research and development technology base. Investment in new discovery tops our list of priorities, which is why we are well-recognised over many diverse therapy areas for both prescription medications, and consumer products that can be bought over-the-counter.
Wyeth improves the lives of millions of people with a wide range of outstanding products. We have three divisions - Wyeth Pharmaceuticals for prescription-only products; SMA Nutrition for baby milks; and Wyeth Consumer Healthcare for over the counter products.
Click here to find out more about SMA Nutrition
Click here to find out more about Wyeth Consumer Healthcare
About Wyeth Vaccines
For many years, Wyeth has been a leader in vaccine development, helping prevent life threatening diseases, and contributing to the eradication of smallpox. By working together with governments and associated agencies, Wyeth Vaccines continues to make a significant contribution to public health both globally and here in the UK.
Most recently, Wyeth has been at the forefront in developing conjugate vaccines to help protect against some of the leading bacterial causes of meningitis and septicaemia, such as Hib (Haemophilus influenzae type b), meningitis C (Neisseria meningitidis type C), and the pneumococcus (Streptococcus pneumoniae).
Hib disease, once a leading cause of bacterial meningitis in infants and young children, has been substantially reduced since the introduction of routine vaccination in the UK in 1992 (Immunisation against Infectious Disease, Chapter 16). Following the inclusion of vaccination against meningitis C in the national immunisation programme in 1999, the UK has observed a similar reduction in the incidence of this form of bacterial meningitis and septicaemia [DoH 2005].
Wyeth has developed a conjugate vaccine against pneumococcal disease, another leading cause of bacterial meningitis and serious infections in infants and young children. The vaccine has now been incorporated into the UK routine childhood immunisation programme, where it is expected to save lives and prevent disability caused by this serious infection.
Contact Us
Wyeth Vaccines
Huntercombe Lane South
Taplow
Maidenhead
Berkshire SL6 0PH
Tel 01628 604377
